Shehnaaz Suliman
CIK: 0001713070
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (14 total)
- Sep 22, 2026TXG
10x Genomics, Inc.
Sale(S)Direct1.2K shares at avg. $82.28$101K - Sep 22, 2026TXG
10x Genomics, Inc.
Sale(S)Direct292 shares at avg. $78.20$23K - Sep 22, 2026TXG
10x Genomics, Inc.
Sale(S)Direct614 shares at avg. $79.51$49K - Sep 22, 2026TXG
10x Genomics, Inc.
Sale(S)Direct1.3K shares at avg. $80.82$107K - Sep 22, 2026TXG
10x Genomics, Inc.
Sale(S)Direct2.3K shares at avg. $81.67$185K - Aug 24, 2026TXG
10x Genomics, Inc.
Sale(S)Direct561 shares at avg. $62.73$35K - Aug 24, 2026TXG
10x Genomics, Inc.
Sale(S)Direct1.6K shares at avg. $63.97$105K - Jun 16, 2026TXG
10x Genomics, Inc.
Sale(S)Direct5.4K shares at avg. $32.59$175K - Jun 16, 2026TXG
10x Genomics, Inc.
Sale(S)Direct364 shares at avg. $33.27$12K - Jun 4, 2026TXG
10x Genomics, Inc.
Award(A)Direct8.8K shares- - May 18, 2026RARE
Ultragenyx Pharmaceutical Inc.
Sale(S)Direct5.7K shares at avg. $25.12$144K - May 14, 2026RARE
Ultragenyx Pharmaceutical Inc.
Award(A)Direct7.8K shares- - Jun 3, 2025TXG
10x Genomics, Inc.
Award(A)Direct15.4K shares- - May 15, 2025RARE
Ultragenyx Pharmaceutical Inc.
Award(A)Direct5.7K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 22, 2026 |  TXG 10x Genomics, Inc. | Sale(S) | 1,222 | $82.28 | $100,542 | Direct |
| Sep 22, 2026 | TXG 10x Genomics, Inc. | Sale(S) | 292 | $78.20 | $22,833 | Direct |
| Sep 22, 2026 | TXG 10x Genomics, Inc. | Sale(S) | 614 | $79.51 | $48,820 | Direct |
| Sep 22, 2026 | TXG 10x Genomics, Inc. | Sale(S) | 1,325 | $80.82 | $107,082 | Direct |
| Sep 22, 2026 | TXG 10x Genomics, Inc. | Sale(S) | 2,270 | $81.67 | $185,391 | Direct |
| Aug 24, 2026 | TXG 10x Genomics, Inc. | Sale(S) | 561 | $62.73 | $35,189 | Direct |
| Aug 24, 2026 | TXG 10x Genomics, Inc. | Sale(S) | 1,646 | $63.97 | $105,289 | Direct |
| Jun 16, 2026 | TXG 10x Genomics, Inc. | Sale(S) | 5,359 | $32.59 | $174,644 | Direct |
| Jun 16, 2026 | TXG 10x Genomics, Inc. | Sale(S) | 364 | $33.27 | $12,112 | Direct |
| Jun 4, 2026 | TXG 10x Genomics, Inc. | Award(A) | 8,829 | - | $0 | Direct |
| May 18, 2026 |  RARE Ultragenyx Pharmaceutical Inc. | Sale(S) | 5,740 | $25.12 | $144,189 | Direct |
| May 14, 2026 | RARE Ultragenyx Pharmaceutical Inc. | Award(A) | 7,751 | - | $0 | Direct |
| Jun 3, 2025 | TXG 10x Genomics, Inc. | Award(A) | 15,357 | - | - | Direct |
| May 15, 2025 | RARE Ultragenyx Pharmaceutical Inc. | Award(A) | 5,740 | - | - | Direct |
1-14 of 14 transactions
About SULIMAN SHEHNAAZ
SULIMAN SHEHNAAZ (SEC CIK 0001713070) files insider reports with the SEC as Director of 10x Genomics, Inc. (TXG) and Director of Ultragenyx Pharmaceutical Inc. (RARE).
Signal8 holds 7 ownership filings by SULIMAN SHEHNAAZ, all Form 4s, filed between May 19, 2025 and Sep 24, 2026. Those filings report 14 transactions, from May 15, 2025 to Sep 22, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on SULIMAN SHEHNAAZ's filings is in PLEASANTON, CA.
Recent filings by SULIMAN SHEHNAAZ
- Sep 22, 2026: Open-market sales of TXG shares (5 lines, Form 4, code S).
- Aug 24, 2026: Open-market sales of TXG shares (2 lines, Form 4, code S).
- Jun 16, 2026: Open-market sales of TXG shares (2 lines, Form 4, code S).
- Jun 4, 2026: Grant or award of TXG shares (Form 4, code A).
- May 18, 2026: Open-market sale of RARE shares (Form 4, code S).
Other insiders filing for 10x Genomics, Inc. (TXG)
- Saxonov Serge, Chief Executive Officer
- Taich Adam, Chief Financial Officer
- STUELPNAGEL JOHN R, Director
- Hindson Benjamin J.
- Teichmann Sarah A., Director
- Popovits Kimberly J, Director